Status:
COMPLETED
Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001
Lead Sponsor:
Duke University
Collaborating Sponsors:
United States Department of Defense
Conditions:
Metastatic Hormone Refractory Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to look at the genetic changes that RAD001 causes in prostate cancer cells and how those changes relate to patients' response to RAD001 treatment.
Detailed Description
This correlative science study will be a minimum risk assessment of tumor and plasma samples collected as part of a Phase II clinical trial of RAD001 in patients with HRPC. Prior to enrollment or at t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients must be enrolled in the clinical study entitled: A Single Arm, Phase II Study of RAD001 in Patients with Metastatic, Hormone-Refractory Prostate Cancer at the time of enrollment onto this study.
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00636090
Start Date
January 1 2007
End Date
January 1 2010
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710